Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
Department of Global and Continuing Education, Harvard Medical School, Boston, Massachusetts.
Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1483-1490. doi: 10.1158/1055-9965.EPI-18-0203. Epub 2018 Sep 20.
Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer.
We used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA125II assay and calculated the association between medical conditions and log-transformed CA125 using linear regression.
The median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/mL for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps ( = 0.06) and hysterectomy ( = 0.01) and significantly higher with endometriosis ( = 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) ( < 0.01, = 2 cases) but not among postmenopausal with CVD ( = 79). Furthermore, among postmenopausal women, CA125 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis ( = 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease ( = 0.04).
Several chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening.
Consideration of chronic medical conditions may be necessary to interpret CA125 values.
使用生物标志物癌抗原(CA)125 进行的随机试验,无论是否联合盆腔超声,都未能显示出对卵巢癌进行普通人群筛查的明确益处。部分原因可能是缺乏关于除卵巢癌以外可以改变 CA125 水平并影响特异性或敏感性的其他情况的信息。我们评估了在没有卵巢癌的女性中常见医疗状况与 CA125 水平之间的关联。
我们使用了 1992 年至 2008 年期间参加新英格兰病例对照研究的 2004 名没有卵巢癌的女性的数据和样本。参与者在入组时完成了面对面访谈并捐献了血样。我们使用 CA125II 测定法测量 CA125,并使用线性回归计算医疗状况与对数转换的 CA125 之间的关联。
参与者的中位年龄为 53 岁,1119 名(56%)为绝经后。绝经前女性的平均 CA125 水平为 14.5 单位/mL,绝经后女性为 11.7 单位/mL。在绝经前女性中,CA125 明显低于结肠息肉( = 0.06)和子宫切除术( = 0.01)的女性,明显高于子宫内膜异位症( = 0.05)的女性。绝经前患有冠心病(CVD)的女性 CA125 也明显升高( < 0.01, = 2 例),但绝经后患有 CVD 的女性则没有( = 79)。此外,在绝经后女性中,患有骨质疏松症、高胆固醇血症和骨关节炎的女性 CA125 明显降低( = 0.03、0.02 和 0.01),而患有炎症性肠病的女性 CA125 明显升高( = 0.04)。
一些慢性疾病与 CA125 相关,这可能会影响卵巢癌筛查中 CA125 的解释。
解释 CA125 值时可能需要考虑慢性医疗状况。